Data from Lifecare's Clinical Development Study LFC-SEN-001 was presented at the
American Diabetes Association (ADA) Scientific Sessions 2023. Lifecare's poster
presentation reveals the study background, methods, and results. The results
include an impressive mean average of absolute error (MARD) of 9,6%, positioning
Lifecares's Sencell technology with an accuracy that is acceptable for
therapeutic (medical) decisions such as insulin dose adjustments. Furthermore,
the study results include a consensus error grid analysis that confirms that all
the 261 data points collected in the study is within zones A and B, meaning that
the study results meet regulatory requirements for Continuous Glucose Monitoring
systems.
The poster presentation is enclosed to this stock exchange notification and on
the following link:
https://lifecare.no/news/proof-of-concept-study-results-presented-at-ada-2023/
and enclosed as attachment to this .
On the basis of the study results and conclusion, Lifecare will evaluate the
scope of the planned upcoming study LFC-SEN-002. The purpose of the study is to
investigate longevity and biocompatibility in live tissue. In light of the very
encouraging outcomes of study LFS-SEN-001, Lifecare will consider adjusting the
planned study to take advantage of technical and strategic synergies that can
lead to a shorter time to market within the broad field of glucose monitoring.
For media inquiries or more information, please contact: Asle Wingsternes, Head
of Communications and Public Affairs at Lifecare, telephone +47 41 61 42 52,
asle.wingsternes@lifecare.no
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Joacim Holter, CEO at Lifecare AS, on 27 June 2023
at 08:00 CET
_____________________________________________________
Lifecare AS is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on
the sensor body for read-out of pressure variations. LifecareŽs sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the human
body.